Turnstone Biologics
Turnstone Biologics

Turnstone’s platform and intellectual property are based on discoveries from leading researchers in the oncolytic viral immunotherapy field including John Bell, Ph.D., Brian Lichty, Ph.D., and David Stojdl, Ph.D. Four Canadian academic institutes, together with the Fight Against Cancer Innovation Trust (FACIT), have advanced Turnstone’s lead immunotherapy product into a Phase I/II clinical development study in advanced cancer patients.
San Francisco, CA, USA
Inaccurate data? Flag it here.
Open jobs at Turnstone Biologics
We only use strictly necessary, first-party cookies on this job board. These are cookies that are necessary to deliver this service to you, or are necessary for Ontario Bioscience Innovation Organization to understand how it is being used. Read our Cookie Policy.